Why this ASX healthcare share is soaring 26% on study findings

This share is getting a lot of attention on Monday. What's happening?

| More on:
Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Orthocell Ltd (ASX: OCC) shares are starting the week with a very big bang.

In morning trade, the ASX healthcare share is up 26% to a 52-week high of $1.02.

Why is the ASX healthcare share soaring today?

Investors have been fighting to get hold of the regenerative medicine company's shares on Monday after it released a major announcement.

According to the release, Orthocell has successfully completed its Remplir 510(k) nerve repair study.

As you might have guessed from the share price reaction, the news was good. Management revealed that the study validates Remplir as safe and effective for use in the surgical repair of peripheral nerves.

The company notes that the U.S. Regulatory Study is a key component of the FDA submission to gain U.S. marketing clearance. As a result, the ASX healthcare share believes it is on schedule to submit its 510(k) application this month.

After which, if everything goes to plan, U.S. FDA clearance is expected in the first quarter of 2025, with commercial distribution to follow soon after.

The study was undertaken in collaboration with a couple of highly regarded research scientists. Pleasingly, the study met all required endpoints and outcomes.

Use of Remplir to repair the severed sciatic nerves resulted in a return of motor function, a return of sensory function, no adverse tissue reactions (providing strong evidence of biocompatibility), and the regeneration of high-quality nerve tissue.

Furthermore, management highlights that the study outcomes reinforce the clinical results, indicating consistent and predictable return of upper arm and hand function following nerve repair with Remplir.

What's the opportunity?

The ASX healthcare share notes that US FDA approval would open the company up to a major addressable market.

It highlights that the U.S. market is estimated to be worth in excess of U.S. $1.6 billion per annum and growing.

Orthocell's CEO, Paul Anderson, said:

We are thrilled with the results from our U.S. Regulatory Study, validating the superior Remplir clinical outcomes, previously published in a highly regarded, peer reviewed journal. The Study results provide key data for the FDA submission to gain market clearance and start selling Remplir in the U.S. We believe Remplir will redefine the nerve repair market and become an important element in the success of nerve repair surgery.

And with approximately $33 million in cash and no debt, management believes the ASX healthcare share is well-positioned to successfully launch Remplir in Singapore and other key markets including United States, South East Asia, Canada and the EU/UK.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »